Our approach

Apeiron Partners is a new fund of venture funds started in 2021 by Christian Angermayer’s Apeiron Investment Group and Nick Nigam.

We invest in access-constrained, remarkable fund managers, who have a high conviction approach and bold thesis for the future. Our core focus is emerging early-stage venture funds, but we also construct selected positions in top performing established funds.

We believe innovation-driven entrepreneurship is accelerating in communities across the world and are therefore geo-agnostic in our approach. We are committed to diversity and inclusion in our portfolio and building long-term partnerships with our managers across fund cycles.

Venture capital has outperformed every major asset class in recent years – and we expect it to remain the best asset class going forward.



Apeiron Partners is anchored by Christian Angermayer’s Apeiron Investment Group.

Apeiron Investment Group is the private investment firm of entrepreneur and investor Christian Angermayer. Apeiron invests globally into the most exciting and world-changing tech & biotech companies with a hands-on, entrepreneurial investment approach.

Its global presence, $3.5+ billion AUM, and own three emerging venture capital funds, provides a powerful platform for Apeiron Partners to be strategic investors to our fund managers and accelerate their success.

Apeiron Partners is a sister fund to Presight Capital, Apeiron’s flagship global venture capital fund that invests across sectors and stages in the most ambitious founders. We also work closely with Apeiron’s other emerging funds: re:Mind and Elevat3 Capital.

With Apeiron Partners, we exercise the same entrepreneurial and value add approach to investing in funds as we have when investing directly in companies.

— Christian Angermayer, General Partner, Founder of Apeiron Investment Group

Who we are

Christian Angermayer


Christian Angermayer is founder of Apeiron Investment Group. In 2000, Christian co-founded Ribopharma (original patents for RNAi technology) which merged with the listed US SPAC Alnylam. Christian has since created and invested in numerous companies, raised $2bn+ for his portfolio companies, and been involved in 50+ IPO and M&A transactions as entrepreneur, investor or advisor. A huge part of Christian’s investments center around helping the world live a healthier, happier, and longer life. With atai Life Sciences, which he founded in 2018, Christian is developing a pipeline of therapeutic candidates, including psychedelics, targeted at prevalent and damaging mental health illnesses. And with his biotech companies Rejuveron and Cambrian, Christian is developing medical drugs with the potential to significantly prolong the human life span.
Discover more Discover more



Nick is Co-Founder and Managing Partner at Apeiron Partners. He was formerly an early stage venture capital investor for six years at Samsung Next – firstly in Silicon Valley and New York, and then Berlin, where he helped establish and operationalize the group’s Europe presence. As a UK qualified lawyer, he advised on a wide range of banking, finance, and other corporate matters, for five years at Morgan Lewis and Dewey & LeBoeuf in London and Moscow. Nick received an MBA from MIT and a Bachelor of Laws from the University of Nottingham. A third culture kid from Hong Kong, he is settled (for now..) in Berlin by way of 11 cities across Asia, Europe, and the US.
Discover more Discover more



Fabian Hansen is the co-founder and Managing Director of Presight Capital, the direct investment sister fund to Apeiron Partners. Over the years, Fabian was an early investor in numerous category-defining companies including AbCellera, Razor group, Velocity, Syfe, Peptilogics, ATAI, Compass Pathways, AngieX, Sensei, Rational Vaccines, ChemomAb. Fabian serves on the board of Peptilogics, Alloy and Angiex.
Discover more Discover more